Navamedic 

SEK18.50
10
+SEK0.00+0% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
18.5
52W Low
18.5
Volume
-
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
May 10
SEK1.22
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.73
-0.3
0.13
0.56
Expected EPS
-0.0519215672
Actual EPS
N/A

Financials

-4.16%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
522.59MRevenue
-21.72MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NAVAO.ST. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap205.97B
Novo Nordisk is a global healthcare company and a leading competitor in the pharmaceuticals sector, directly competing with Navamedic ASA in areas such as diabetes care and biopharmaceuticals.
Pfizer
PFE
Mkt Cap162.16B
Pfizer is a global biopharmaceutical company that competes with Navamedic ASA in the development and marketing of medications and healthcare products.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. is a global healthcare company that competes with Navamedic ASA in the pharmaceuticals sector, offering similar products in various therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson is a comprehensive healthcare company that competes across multiple segments, including pharmaceuticals, medical devices, and consumer health products, overlapping with Navamedic's market.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie is a research-based biopharmaceutical company that competes with Navamedic ASA in developing and marketing advanced therapies.
GSK
GSK
Mkt Cap99.96B
GlaxoSmithKline is a global healthcare company that competes with Navamedic ASA in the pharmaceutical and healthcare product sectors, including prescription medicines and vaccines.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Navamedic ASA in developing and commercializing prescription medicines in various therapeutic areas.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Navamedic ASA in the discovery, development, and delivery of medicines.
Sanofi
SNY
Mkt Cap106.01B
Sanofi is a global healthcare leader that competes with Navamedic ASA in the pharmaceuticals sector, offering a wide range of medicines and vaccines.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.37B
Teva Pharmaceutical Industries Ltd. is a global leader in generic and specialty medicines, competing with Navamedic ASA in the generics market and in the development of new treatments.

About

Navamedic ASA, an Oslo, Norway-based pharmaceutical firm established in 2002 and formerly known as Glucomed AS until its name change in 2004, operates across Northern Europe. The company is actively involved in the entire lifecycle of pharmaceutical and related goods, from development and manufacturing to their commercialization and distribution. Its comprehensive portfolio encompasses a diverse range of products, including prescribed and over-the-counter medications, specialized medical nutrition, medical devices, dietary supplements, and cosmetic items. A significant portion of its offerings is dedicated to medical nutrition, formulated to address various metabolic disorders such as phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders. These nutritional solutions also cater to conditions like glycogen storage diseases, renal diseases, fat metabolism issues, malnutrition, and support for ketogenic diets. Furthermore, Navamedic features a consumer health division providing non-prescription drugs and wellness products for common ailments including pain relief, coughs, colds, gastrointestinal issues, and women's health, primarily distributed through pharmacies and drugstores. The company also supplies specialty pharmaceuticals targeting specific therapeutic areas such as dermatology, wound care, women's health, urology, and obesity. Completing its product line are branded generics, notably in cardiology and antibiotics. Its widespread distribution network ensures products reach hospitals, individual patients, and retail pharmacies throughout its operational regions.
Show more...
CEO
Lars Minor
Employees
38
Country
Other
ISIN
NO0010205966
WKN
000A0JKUU

Listings

0 Comments

Share your thoughts

FAQ

What is Navamedic stock price today?
The current price of NAVAO.ST is SEK18.50 SEK — it has increased by +0% in the past 24 hours. Watch Navamedic stock price performance more closely on the chart.
What is Navamedic stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Navamedic stocks are traded under the ticker NAVAO.ST.
When is the next Navamedic earnings date?
Navamedic is going to release the next earnings report on October 29, 2026.
What were Navamedic earnings last quarter?
NAVAO.ST earnings for the last quarter are -0.12 SEK per share, whereas the estimation was -0.02 SEK resulting in a -500% surprise. The estimated earnings for the next quarter are N/A SEK per share.
What is Navamedic revenue for the last year?
Navamedic revenue for the last year amounts to 522.59M SEK.
What is Navamedic net income for the last year?
NAVAO.ST net income for the last year is -21.72M SEK.
Does Navamedic pay dividends?
Yes, NAVAO.ST dividends are paid annual. The last dividend per share was 1.22 SEK. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Navamedic have?
As of September 10, 2026, the company has 38 employees.
In which sector is Navamedic located?
Navamedic operates in the Health & Wellness sector.
When did Navamedic complete a stock split?
Navamedic has not had any recent stock splits.
Where is Navamedic headquartered?
Navamedic is headquartered in Oslo, Other.